Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 607

2.

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.

Circulation. 2001 Nov 6;104(19):2280-8.

3.
4.

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

Arch Intern Med. 2000 Oct 23;160(19):2998-3003.

PMID:
11041909
5.

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

Weir MR, Sperling RS, Reicin A, Gertz BJ.

Am Heart J. 2003 Oct;146(4):591-604. Review.

PMID:
14564311
6.
7.

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

JAMA. 1999 Nov 24;282(20):1929-33.

PMID:
10580458
9.

Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.

Weaver AL, Messner RP, Storms WW, Polis AB, Najarian DK, Petruschke RA, Geba GP, Tershakovec AM.

J Clin Rheumatol. 2006 Feb;12(1):17-25.

PMID:
16484875
10.

Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.

Curtis SP, Ko AT, Bolognese JA, Cavanaugh PF, Reicin AS.

Curr Med Res Opin. 2006 Dec;22(12):2365-74.

PMID:
17265571
11.

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.

Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.

Clin Ther. 2005 Aug;27(8):1196-214. Review.

PMID:
16199245
12.

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.

Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.

Am J Gastroenterol. 2003 Aug;98(8):1725-33.

PMID:
12907325
13.

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.

Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seidenberg B, Ehrich E.

Arch Intern Med. 2000 Jun 26;160(12):1781-7.

PMID:
10871971
14.

Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.

Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.

Circulation. 2006 Jun 27;113(25):2906-13. Epub 2006 Jun 19.

15.

Current perspective on the cardiovascular effects of coxibs.

Konstam MA, Weir MR.

Cleve Clin J Med. 2002;69 Suppl 1:SI47-52. Review.

PMID:
12086293
16.

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC; VICTOR Trial Group.

N Engl J Med. 2007 Jul 26;357(4):360-9.

17.

Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.

Bannwarth B, Berenbaum F.

Expert Opin Investig Drugs. 2005 Apr;14(4):521-33. Review.

PMID:
15882125
18.
19.

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.

White WB, Faich G, Borer JS, Makuch RW.

Am J Cardiol. 2003 Aug 15;92(4):411-8.

PMID:
12914871
20.

Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.

White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM.

Am J Cardiol. 2007 Jan 1;99(1):91-8. Epub 2006 Nov 10.

PMID:
17196469
Items per page

Supplemental Content

Write to the Help Desk